

What is claimed is:

1. An implantable drug delivery system comprising:
  - a housing suitable for implantation in a patient;
  - storage means for storing a quantity of drug in a dry powder form,
  - metering means for metering a predetermined, effective amount of the drug; and
  - delivery means for delivering an effective amount of the drug to a patient to treat a disorder.
2. An implantable drug delivery system according to claim 1 wherein the delivery means comprises:
  - a catheter having a plurality of drug delivery ports, the drug delivery ports being movable between an open position to deliver the drug to the patient, and a closed position; and
  - drug delivery path preservation means for resisting fibrous occlusion of the drug delivery ports.
3. An implantable drug delivery system comprising:
  - a housing suitable for implantation in a patient,
  - a storage chamber for storing a quantity of drug,
  - metering means for metering a predetermined, effective amount of the drug; and
  - delivery means for delivering an effective amount of the drug to a patient to treat a disorder.
4. An implantable drug delivery system according to claim 3 wherein the storage means comprises a plurality of storage compartments,
  - the metering means comprises a plurality of micro-channels capable of communicating with the storage compartments, a mixing chamber, and valve means capable of being opened to afford fluid communication with the storage compartments.

5. An implantable drug delivery system according to claim 4 further comprising indexing means for affording indexed communication between the mixing chamber and a micro-channel.
6. An implantable drug delivery system according to claim 3 wherein the drug comprises prostaglandin E1.
7. An implantable drug delivery system according to claim 3 wherein the system includes a catheter with drug delivery ports that are sized and shaped to be implanted in a corporal body region of the patient.
8. An implantable drug delivery system according to claim 7 wherein the catheter includes a coating of poly(glycine-valine-glycine-valine-proline).
9. An implantable drug delivery system according to claim 3 wherein the device includes a drug delivery port, and storage means for a substance for resisting fibrous occlusion of the drug delivery port.
10. An implantable drug delivery system according to claim 9 wherein the substance for resisting fibrous occlusion comprises a biodegradable polymer.
11. An implantable drug delivery system according to claim 3 wherein the delivery means comprises a pump.
12. An implantable drug delivery system according to claim 4 wherein the valve means are battery powered.
13. An implantable drug delivery system comprising:  
storage means for storing a drug,

metering means for metering a predetermined, effective amount of the drug;  
delivery means for delivering an effective amount of the drug to a patient to treat  
a disorder, the delivery means comprising:

a catheter having a plurality of drug delivery ports, the drug delivery ports being  
movable between an open position to deliver the drug to the patient, and a closed  
position; and

drug delivery path preservation means for resisting fibrous occlusion of the drug  
delivery ports.

14. An implantable drug delivery system according to claim 13, wherein the drug  
delivery path preservation means comprises poly(glycine-valine-glycine-valine-proline)  
associated with the catheter.

15. A drug delivery system according to claim 13, wherein the catheter has a  
longitudinal axis and the drug delivery ports comprise a plurality of slits.

16. An implantable drug delivery system according to claim 13, wherein the drug  
delivery path preservation means comprises a means for delivering a substance for  
resisting fibrous occlusions through the drug delivery ports.

17. An implantable drug delivery system according to claim 13, wherein the drug  
delivery path preservation means comprises a fluid coating on the catheter.

18. An implantable drug delivery system according to claim 13, wherein the drug  
delivery path preservation means comprises a film on the catheter.

19. A method of treating erectile dysfunction comprising the steps of:  
implanting a supply of prostaglandin E1 in the body in a device capable of  
releasing a dose on demand, and  
thereafter treating the erectile dysfunction by releasing an effective amount of  
prostaglandin E1 on demand of the patient.

20. A method of treating erectile dysfunction according to claim 17 further comprising resisting chances of an overdose of the prostaglandin E1 by preventing actuation of the device outside predetermined parameters.